The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

The Western New York Chapter of the Alzheimer’s Association will offer a free education program on recognizing and understanding Alzheimer’s disease and dementia at 10 a.m. Thursday at ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

Eli Lilly said it will spend $1.8 billion to boost production in Ireland of its popular diabetes and weight-loss drugs, along with ingredients for its recently approved Alzheimer’s treatment, Kisunla.

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The FDA has granted approval to 29 novel drugs this year. Innovation in the ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

Tony Downs was a powerhouse lawyer with an uncanny memory before the memory-robbing disease took hold. Now, he and his wife are hoping Leqembi, a newly approved drug, will help slow his decline.

Eli Lilly has again upped the ante in scaling up its manufacturing footprint, this time revealing an investment totaling $1.8 billion to expand production capacity at two plants in Ireland. | Eli ...

Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...